Anti‐IL13 or anti‐IL4 agents vs placebo
Rate of exacerbations requiring systemic corticosteroids · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in exacerbation requiring OCS (rate ratio) compared with placebo (low certainty).
1 finding from 1 review
- Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes onlyRR 0.98 [0.72, 1.32]1 study · 452 participantsLow